Oral trovafloxacin compared with intravenous cefoxitin in the prevention of bacterial infection after elective vaginal or abdominal hysterectomy for nonmalignant disease

American Journal of Surgery

Volumn 176, Issue 6 A, 1998, Pages 62S-66S

  Roy, Subir ^a,g   Hemsell, David ^b   Gordon, Stephen ^c   Godwin, David ^d   Pearlman, Mark ^e   Luke, David ^f  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c Crucible Group Inc   (United States)

^d Upstate Clinical Research Inc   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f PFIZER INC   (United States)

^g WOMEN S AND CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOXITIN; PLACEBO; TROVAFLOXACIN;

ABDOMINAL HYSTERECTOMY; ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ELECTIVE SURGERY; FEMALE; GYNECOLOGIC INFECTION; HUMAN; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VAGINAL HYSTERECTOMY;

EID: 0032459108     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00222-0     Document Type: Article

References (29)

1. Antimicrobial prophylaxis in surgery. Med Lett Drugs Ther. 1995;37:79-82.
2. Hemsell DL. Prophylactic antibiotics in gynecologic and obstetric surgery. Rev Infect Dis. 1991;13(suppl 10):S821-S841.
3. Committee on Gynecologic Practice. Prophylactic use of antibiotics with abdominal hysterectomy. ACOG Committee Opinion. 1990;82:33.
4. Wittewaall-Evelaar EW, Verbrugh HA, Kroeks MVAM, Haspels AA. Antibiotic prophylaxis in elective abdominal hysterectomy: a meta-analysis. Contemp Rev Obstet Gynaecol. 1992; 4:202-208.
5. Mittendorf R, Aronson MP, Berry RE, et al. Avoiding serious infections associated with abdominal hysterectomy: a meta-analysis of antibiotic prophylaxis. Am J Obstet Gynecol. 1993;169:1119-1124.
6. Tanos V, Rojansky N. Prophylactic antibiotics in abdominal hysterectomy. J Am Coll Surg. 1994;179;593-600.
7. Hemsell DL, Cunningham FG, Kappus S, Nobles B. Cefoxitin for prophylaxis in premenopausal women undergoing vaginal hysterectomy. Obstet Gynecol. 1980;56:629-634.
8. Berkeley AS, Orr JW, Cavanagh D, et al. Comparative effectiveness and safety of cefotetan and cefoxitin as prophylactic agents in patients undergoing abdominal or vaginal hysterectomy. Am J Surg. 1988;155:81-85.
9. McGregor JA, Phillips LE, Roy S, et al. Results of a double-blind, placebo-controlled clinical trial program of single-dose ceftizoxime versus multiple-dose cefoxitin as prophylaxis for patients undergoing vaginal and abdominal hysterectomy. J Am Coll Surg. 1994;178:123-131.
10. Briggs Gooding B, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother. 1993;37:349-353.
11. Eliopoulos GM, Klimm K, Eliopoulos CT, et al. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of grampositive bacteria. Antimicrob Agents Chemother. 1993;37:366-370.
12. Neu HC, Chin N-X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994;38:2615-2622.
13. Coque TM, Singh KV, Murray BE. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against grampositive cocci. J Antimicrob Chemother. 1996;37:1011-1016.
14. Fuchs PC, Barry AL, Brown SD, Sewell DL. In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. Eur J Clin Microbiol Infect Dis. 1996;15:678-682.
15. Wexler HM, Molitoris E, Molitoris D, Finegold SM. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother. 1996;40:2232-2235.
16. Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. J Antimicrob Chemother. 1997;39(suppl B):43-49.
17. Girard AE, Girard D, Gootz TD, et al. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother. 1995;39:2210-2216.
18. Thadepalli H, Reddy U, Chuah SK, et al. In vivo efficacy of trovafloxacin (CP-99,217), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother. 1997;41:583-586.
19. Martens M, Maccato M, Van Hook C, Vincent J. Penetration of trovafloxacin into gynecologic tissues. Am J Surg. 1998;176(Suppl 6A):18S-22S.
20. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):1-14.
21. Teng R, Dogolo LC, Willavize SA, et al. Oral bioavailability of trovafloxacin with and without food in healthy volunteers. J Antimicrob Chemother. 1997;39(suppl B):87-92.
22. Teng R, Dogolo LC, Willavize SA, et al. Effect of Maalox and omeprazole on the bioavailability of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):93-97.
23. Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother. 1995;36:385-394.
24. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother. 1996;37:955-963.
25. Gibbs CP, Banner TC. Effectiveness of Bicitra® as a preoperative antacid. Anesthesiology. 1984;61:97-99.
26. Manchikanti L, Grow JB, Colliver JA, et al. Bicitra® (sodium citrate) and metoclopramide in outpatient anesthesia for prophylaxis against aspiration pneumonitis. Anesthesiology. 1985;63:378-384.
27. Williams DJ, Hopkins S. Safety and tolerability of intravenous to oral treatment and single dose intravenous or oral prophylaxis with trovafloxacin. Am J Surg. 1998;176(Suppl 6A):74S-79S.
28. Nichols RL. Surgical infections: prevention and treatment -1965 to 1995. Am J Surg. 1996;172:68-74.
29. Hemsell DL, Reisch J, Nobles B, Hemsell PG. Prevention of major infection after elective abdominal hysterectomy: individual determination required. Am J Obstet Gynecol. 1983;147:520-528.